Gilead Sciences, Inc. vs PAGSEG Inc — how do they compare? Gilead Sciences, Inc. trades at $136.52 (market cap $168.35B), while PAGSEG Inc trades at $8.66 (market cap $2.48B). The key difference: Gilead Sciences, Inc. is far larger — about 67.9× PAGSEG Inc's market cap, and PAGSEG Inc pays the higher dividend (11.7%). Which is the better fit depends on your goals.
| GILD | PAGS | |
|---|---|---|
Market Cap | $168.35B | $2.48B |
Sector | Health | Technology |
52-Week High | $155.80 | $12.00 |
52-Week Low | $110.56 | $8.38 |
Enterprise Value | $191.42B | $10.22B |
Dividend Yield | 2.42% | 11.7% |
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.06, down slightly by 0.11% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 revenue growth of 8% year-over-year, beating estimates, though a net loss of $6.75 per share resulted from acquisition-related costs. Analyst consensus is strongly bullish with a $151.22 price target, and recent news highlights robust HIV drug sales and pipeline progress.
The outlook for GILD is positive, driven by raised 2026 guidance and HIV franchise strength, but risks include patent cliffs by the mid-2030s and integration challenges from acquisitions. Investors should weigh the high valuation multiples against growth potential, with the stock offering upside if execution continues to exceed expectations.
PAGS trades at $8.59, down 5.4% in the last session, with a bearish technical signal despite attractive valuation metrics (P/E 6.17, P/S 0.64). The company reported $20.41B revenue and $2.12B net income for 2025, maintaining stable profitability with a 10.4% net margin. Recent Q2 2026 earnings beat expectations with EPS of $0.41 versus $0.389 expected, while analyst consensus remains bullish with a $11.45 price target.
The stock presents a value opportunity given its discounted valuation and strong analyst support (62.5% buy ratings), but faces headwinds from technical weakness and competitive pressures in Brazil's digital banking sector. Upside potential exists if earnings momentum continues, though investors should monitor execution risks and macroeconomic conditions affecting Brazilian financial markets.
Trailing returns across standard periods
Latest headlines on both assets
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →